TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24792106

Group type: EXPERIMENTAL
Intervention: OZil Intelligent Phaco torsional mode (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Combined torsional/longitudinal ultrasound mode (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison between Group 1 and Group 2
Number of subjects: 80
Study: 22789884

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Prasugrel 10 mg once daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 44

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 44
Study: 21186969

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 20-70 mg/day
Number of subjects: 0
Study: 18065591

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 17046

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17046
Study: 16344401

Group type: EXPERIMENTAL
Intervention: PV isolation in combination with linear ablation joining the 2 superior PVs (roofline)
Number of subjects: 90

Group type: COMPARATOR
Intervention: PV isolation alone
Number of subjects: 90
Study: 12487686

Group type: EXPERIMENTAL
Intervention: Hyperoxic submaximal trial (40.18 +/‐ 0.73% O(2); SUB(40))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normoxic submaximal trial (20.93 +/‐ 0.22% O(2); SUB(21))
Number of subjects: 25
Study: 9477394

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 7879931

Group type: EXPERIMENTAL
Intervention: Intraperitoneal morphine (1 mg in 20 ml saline)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intraperitoneal saline and 1 mg intravenous morphine
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (20 ml 0.25%)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Interpleural morphine (1.5 mg in 30 ml saline)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Interpleural saline and 1.5 mg intravenous morphine
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Interpleural bupivacaine (30 ml 0.25%)
Number of subjects: 110
Study: 2121204

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 0
Study: 494997

Group type: EXPERIMENTAL
Intervention: metoclopramide bromide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: metoclopramide chloride
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 30657891

Group type: EXPERIMENTAL
Intervention: Rosuvastatin alone or with candesartan and hydrochlorothiazide (HCT)
Number of subjects: 12705

Group type: EXPERIMENTAL
Intervention: Combination of rosuvastatin with candesartan/HCT
Number of subjects: 12705

Group type: EXPERIMENTAL
Intervention: Rosuvastatin and candesartan/HCT
Number of subjects: 12705

Group type: EXPERIMENTAL
Intervention: Cheapest equivalent substitutes
Number of subjects: 12705
Study: 27839957

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 120

Group type: COMPARATOR
Intervention: PO acetaminophen
Number of subjects: 120
Study: 26131808

Group type: EXPERIMENTAL
Intervention: Vascular access dysfunction
Number of subjects: 26133

Group type: EXPERIMENTAL
Intervention: Vascular access dysfunction frequency (≥3 events)
Number of subjects: 26133

Group type: COMPARATOR
Intervention: Control group (no vascular access dysfunction)
Number of subjects: 26133
Study: 23246081

Group type: EXPERIMENTAL
Intervention: Lower resting ankle-brachial index (ABI)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lower resting ABI
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Reduced bilateral hip extensor strength
Number of subjects: 22
Study: 21882799

Group type: EXPERIMENTAL
Intervention: Case management (CM) plus usual nursing care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual nursing care alone
Number of subjects: 0
Study: 19207601

Group type: EXPERIMENTAL
Intervention: Etravirine 800 mg bid (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg bid (Study 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg once a day
Number of subjects: 0
Study: 17227264

Group type: EXPERIMENTAL
Intervention: Heparin (500 IU) in normal saline (HS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 65
Study: 12699950

Group type: EXPERIMENTAL
Intervention: Retrograde catheterisation of the aortic valve (n=101)
Number of subjects: 152

Group type: COMPARATOR
Intervention: No passage through the aortic valve (n=51)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (n=32)
Number of subjects: 152
Study: 10745070

Group type: EXPERIMENTAL
Intervention: Lunelle Monthly Contraceptive Injection (MPA/E(2)C)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Ortho-Novum 7/7/7 (NET/EE)
Number of subjects: 207
Study: 9193192

Group type: EXPERIMENTAL
Intervention: Intravenous meta-chlorophenylpiperazine (mCPP) 0.1 mg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8262115

Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Luteinizing hormone-releasing hormone analogue depot preparation and flutamide
Number of subjects: 76
Study: 3543785

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Healon)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Balanced Saline Solution (BSS)
Number of subjects: 175
Study: 30130990

Group type: EXPERIMENTAL
Intervention: Mobile application 'Karada‐no‐kimochi'
Number of subjects: 1526

Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 1526
Study: 26171678

Group type: EXPERIMENTAL
Intervention: Aquacel Ag dressing
Number of subjects: 89

Group type: COMPARATOR
Intervention: Acticoat dressing
Number of subjects: 89
Study: 25198033

Group type: EXPERIMENTAL
Intervention: Hydrodebrider sinus irrigation (HSI)
Number of subjects: 12
Study: 22744718

Group type: EXPERIMENTAL
Intervention: Short- and long-term antibiotic treatments
Number of subjects: 434
Study: 20431220

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lidocaine 1.0%
Number of subjects: 50
Study: 18986066

Group type: EXPERIMENTAL
Intervention: Facial biological motion recognition task
Number of subjects: 54
Study: 15583913

Group type: EXPERIMENTAL
Intervention: BMIPP imaging (normal uptake)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: sTL imaging (SDS <3 but impaired BMIPP uptake)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: sTL imaging (SDS <3)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: BMIPP imaging (reduced uptake)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: sTL imaging (SDS >=3)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Reduced ejection fraction
Number of subjects: 167
Study: 11488118

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solution
Number of subjects: 638

Group type: COMPARATOR
Intervention: Standard polyethylene glycol preparation
Number of subjects: 638
Study: 9232521

Group type: EXPERIMENTAL
Intervention: RheothRx injection (poloxamer 188) administered as an intravenous infusion at doses of 10, 30, and 45 mg/kg/h for 72 h, 60 mg/kg/h for 43.3 to 72 h, 60 and 90 mg/kg/h for 24 h
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8121319

Group type: EXPERIMENTAL
Intervention: Buflomedil (600 mg per day for 21 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3674301

Group type: EXPERIMENTAL
Intervention: Sleep-deprived condition (defined as less than 3 hours of sleep in a 24 hour period)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsleep-deprived condition
Number of subjects: 0
Study: 29914698

Group type: EXPERIMENTAL
Intervention: 25°C environment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 35°C environment
Number of subjects: 28

Group type: COMPARATOR
Intervention: 15°C environment
Number of subjects: 28
Study: 27267983

Group type: EXPERIMENTAL
Intervention: Multimodal educational intervention consisting of two online modules, a face-to-face workshop for GP trainees, a face-to-face workshop for their supervisors, and case-based discussions in weekly meetings.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-equivalent control group design)
Number of subjects: 0
Study: 23521046

Group type: EXPERIMENTAL
Intervention: Solution-Focused Brief Therapy (SFBT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 38
Study: 23845078

Group type: EXPERIMENTAL
Intervention: Pregabalin with usual care (n = 102)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo with usual care (n = 102)
Number of subjects: 204
Study: 21180396

Group type: EXPERIMENTAL
Intervention: Toothbrushes priced between 1 and 2 Euro (Category B)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Toothbrushes priced at over 2 Euro (Category C)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Toothbrushes priced under 1 Euro (Category A)
Number of subjects: 140
Study: 18383539

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg plus MTX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg every 2 weeks plus MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 0
Study: 16009466

Group type: EXPERIMENTAL
Intervention: Highest tertile of testosterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highest tertile of estradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highest tertile of SHBG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lowest tertile of testosterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lowest tertile of estradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lowest tertile of SHBG
Number of subjects: 0
Study: 12580985

Group type: EXPERIMENTAL
Intervention: High enalaprilat concentration (above 50 ng ml(‐1), n = 17)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low enalaprilat concentration (below 10 ng ml(‐1), n = 18)
Number of subjects: 35
Study: 11966062

Group type: EXPERIMENTAL
Intervention: Single dose of oral prednisolone (30 mg if age < 5 years; 60 mg if age > 5 years)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 8651631

Group type: EXPERIMENTAL
Intervention: Acyclovir-prednisone
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo-prednisone
Number of subjects: 99
Study: 1460160

Group type: EXPERIMENTAL
Intervention: 6-week class and discussion group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-unit self-help manual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-hr feedback and advice session with professional staff
Number of subjects: 0
Study: 2983641

Group type: EXPERIMENTAL
Intervention: Oral estrogen treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29045621

Group type: EXPERIMENTAL
Intervention: Use of proton pump inhibitors (PPIs)
Number of subjects: 16704

Group type: EXPERIMENTAL
Intervention: Cumulative duration of PPIs use (per month)
Number of subjects: 16704

Group type: EXPERIMENTAL
Intervention: Cumulative dosage of PPIs use (per microgram)
Number of subjects: 16704
Study: 26175036

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser, NB‐UVB phototherapy, and 0.05% clobetasol propionate cream (Group A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: NB‐UVB phototherapy and 0.05% clobetasol propionate cream (Group B)
Number of subjects: 27
Study: 24559757

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional method (Control)
Number of subjects: 10
Study: 21520391

Group type: EXPERIMENTAL
Intervention: Radpad radiation shield
Number of subjects: 60

Group type: COMPARATOR
Intervention: No radiation shield protection
Number of subjects: 60
Study: 21187536

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - 10 mg per kg body weight, administered intravenously 10 minutes prior to incision
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no TA)
Number of subjects: 42
Study: 17982182

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose and 10 mg daily maintenance dose)
Number of subjects: 13608

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading dose and 75 mg daily maintenance dose)
Number of subjects: 13608

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13608

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13608
Study: 15476575

Group type: COMPARATOR
Intervention: Calcium and cholecalciferol supplement (500 mg of elemental calcium and 400 IU cholecalciferol)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neridronate (25 mg intramuscularly every month) in addition to calcium and cholecalciferol supplement
Number of subjects: 48
Study: 11511426

Group type: EXPERIMENTAL
Intervention: Cardiac IL6 mRNA levels in patients with advanced heart failure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Left ventricular IL6 mRNA levels
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Right ventricular IL6 mRNA levels
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL6R expression
Number of subjects: 20
Study: 11825486

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) with total parenteral nutrition (TPN) for 7 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: total parenteral nutrition (TPN) only for 7 days
Number of subjects: 17
Study: 8164328

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) continuous infusion at a rate of 50 ng.kg‐1 x min‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) continuous infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 2450113

Group type: EXPERIMENTAL
Intervention: Topical flunisolide (50 micrograms, each nostril, twice daily) for 1 week before antigen challenge
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study: 31351135

Group type: EXPERIMENTAL
Intervention: Onsite specimen processing
Number of subjects: 62

Group type: COMPARATOR
Intervention: Offsite specimen processing
Number of subjects: 62
Study: 30018101

Group type: EXPERIMENTAL
Intervention: Learning Clubs intervention (structured programme with 20 modules, facilitated groups, and home visits)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 1008
Study: 26857054

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 312
Study: 24200335

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - participated in a physical conditioning program throughout pregnancy, 55-60 minutes, 3 days per week
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control Group (CG) - no exercise program
Number of subjects: 200
Study: 24367946

Group type: EXPERIMENTAL
Intervention: PALM (formula containing palm olein, palm kernel oil, and canola oil)
Number of subjects: 33

Group type: COMPARATOR
Intervention: NoPALM (formula without palm olein, palm kernel oil, and canola oil)
Number of subjects: 33
Study: 20487046

Group type: EXPERIMENTAL
Intervention: Combination therapy (dutasteride 0.5 mg + tamsulosin 0.4 mg)
Number of subjects: 4844

Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg
Number of subjects: 4844

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 4844

Group type: EXPERIMENTAL
Intervention: Combination therapy (dutasteride + tamsulosin)
Number of subjects: 4844
Study: 17935974

Group type: EXPERIMENTAL
Intervention: Rituximab (Rit) as a single agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab (Rit) in combination with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of Rituximab to standard chemotherapy
Number of subjects: 0
Study: 16632079

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study: 14660152

Group type: EXPERIMENTAL
Intervention: Methamphetamine users (women) reporting abuse or violence from a partner
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Methamphetamine users (men) reporting violence from friends and others
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Methamphetamine users reporting threatening or coercive experiences with partners
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Methamphetamine users entering treatment for methamphetamine dependence
Number of subjects: 1016
Study: 15471834

Group type: COMPARATOR
Intervention: 123I‐FP‐CIT binding (normal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 123I‐FP‐CIT binding (abnormal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L‐dopa therapy response (normal scan)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L‐dopa therapy response (abnormal scan)
Number of subjects: 20
Study: 10404476

Group type: EXPERIMENTAL
Intervention: Post-MI subjects
Number of subjects: 64

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Post-MI subjects with attentional bias
Number of subjects: 64
Study: 7579132

Group type: EXPERIMENTAL
Intervention: Eyeblink classical conditioning (EBCC) performed concurrently with tapping
Number of subjects: 140

Group type: COMPARATOR
Intervention: Eyeblink classical conditioning (EBCC) performed concurrently with a recognition task or control tasks
Number of subjects: 140
Study: 2105052

Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (15 h/d)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Continuous total parenteral nutrition (24 h/d)
Number of subjects: 5
Study: 6998154

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31652407

Group type: EXPERIMENTAL
Intervention: Greek yogurt (GY) (20 g protein, 208 mg calcium/dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo pudding (PP) (0 g protein, 0 g calcium/dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo pudding (PP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Greek yogurt (GY)
Number of subjects: 30
Study: 28807073

Group type: EXPERIMENTAL
Intervention: VividTrac VT-A100 (VT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: GlideScope Ranger (GL)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Overall (all devices)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Average time to successful intubation for VT
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Average time to successful intubation for GL
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Average time to successful intubation for DL
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Average number of intubation attempts for VT
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Average number of intubation attempts for GL
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Average number of intubation attempts for DL
Number of subjects: 5
Study: 25840299

Group type: EXPERIMENTAL
Intervention: NSAID (ketorolac tromethamine 0.5%)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (ofloxacin 0.3%)
Number of subjects: 2
Study: 24331898

Group type: EXPERIMENTAL
Intervention: OxCAP-MH
Number of subjects: 333
Study: 21225277

Group type: EXPERIMENTAL
Intervention: 2 days/week ATV
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 2 days/week ORM
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 4 days/week ATV
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 4 days/week ORM
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 19254810

Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 382
Study: 17353308

Group type: EXPERIMENTAL
Intervention: Electrocardiogram-synchronized flow-sensitized 4-dimensional MR imaging at 3T
Number of subjects: 0
Study: 15476449

Group type: EXPERIMENTAL
Intervention: Diet plus folic acid (5 mg/day) plus vitamin B12 (500 microg/day) for 1 month
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diet plus placebo for 2 months
Number of subjects: 50
Study: 11503112

Group type: EXPERIMENTAL
Intervention: Pulsed lavage
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study: 9771301

Group type: EXPERIMENTAL
Intervention: Target-controlled alfentanil infusion
Number of subjects: 120

Group type: COMPARATOR
Intervention: Morphine PCA
Number of subjects: 120
Study: 7877587

Group type: EXPERIMENTAL
Intervention: Nipple-preserved mastectomy (Glt+Ax)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 0
Study: 3397586

Group type: EXPERIMENTAL
Intervention: 4‐methylpyrazole in hydrophilic ointment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydrophilic ointment alone
Number of subjects: 12
Study: 31730565

Group type: EXPERIMENTAL
Intervention: CHO + KME (573 mg·kg of a ketone monoester supplement)
Number of subjects: 8

Group type: COMPARATOR
Intervention: CHO + PLA (8% carbohydrate-electrolyte solution)
Number of subjects: 8
Study: 28107844

Group type: EXPERIMENTAL
Intervention: Yoga training (90 min per session, 3 days a week for 8 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 24
Study: 26132839

Group type: EXPERIMENTAL
Intervention: Chikungunya virus (CHIKV) IgG antibodies testing
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Mosquito capture and testing
Number of subjects: 1008
Study: 21666979

Group type: EXPERIMENTAL
Intervention: Multimicronutrients supplementation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (inert compound)
Number of subjects: 36
Study: 19709989

Group type: EXPERIMENTAL
Intervention: Positive credibility cues (trustmarks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Negative credibility cues (adverts, pharmaceutical sponsorship, donation button)
Number of subjects: 85
Study: 17580727

Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 0
Study: 15121070

Group type: EXPERIMENTAL
Intervention: Tilt training (35 patients)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No treatment (controls, 33 patients)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tilt training
Number of subjects: 68